Testosterone replacement therapy: compelling use cases, side effects, and optimal dosing schedules

Peter Attia on TRT: Use Cases, Side Effects, and Dosing Strategy from a Longevity Physician

Peter Attia occupies a unique position in the TRT conversation. He is a physician, a longevity researcher, a public figure who has been transparent about his own hormone optimization journey, and someone who approaches testosterone through the lens of decades-long health outcomes rather than short-term symptom relief. This video represents one of his most thorough discussions of TRT, covering the cases where it makes sense, the side effects worth watching, and the dosing strategies he uses with patients.

What sets this apart from most TRT content is the framework. Attia is not selling testosterone. He is evaluating it as one tool among many in a full approach to healthspan and lifespan extension. That perspective produces a more balanced and ultimately more useful discussion than what you get from most sources.

Compelling Use Cases: When TRT Actually Makes Sense

Attia outlines several categories of patients for whom TRT is clearly indicated. The most straightforward is classic hypogonadism, where a man has symptoms of low testosterone confirmed by lab values consistently below the reference range, and where reversible causes have been ruled out or addressed. This is the textbook case, and most providers agree that TRT is appropriate here.

More interesting is his discussion of the "gray zone" cases. These are men whose total testosterone falls in the low-normal range (say, 300 to 450 ng/dL), who have significant symptoms, and who have not responded to lifestyle optimization (sleep, exercise, stress management, body composition improvement). Attia argues that for some of these men, the risk-benefit calculation favors a trial of TRT, particularly when the alternative is continuing to suffer with symptoms that limit their ability to exercise, work, and engage with life.

He also discusses age-related testosterone decline as a legitimate indication, pushing back against the view that declining testosterone is simply a natural part of aging that should be accepted. His argument is that we do not accept age-related decline in other health markers (we treat high blood pressure, high glucose, and osteoporosis), and treating age-related hormone deficiency is conceptually no different.

Side Effects: An Honest Accounting

Attia runs through the side effect profile of TRT with the kind of clinical precision you would expect from a physician who manages these patients daily. Polycythemia gets significant attention, with Attia emphasizing that hematocrit monitoring is the most important safety measure in TRT management. He notes that the risk is highest in the first year and can often be managed through dosing adjustments rather than requiring phlebotomy.

Fertility suppression is addressed directly, with Attia noting that exogenous testosterone will suppress sperm production in virtually all men. For younger men or those who want to preserve the option of fatherhood, this must be addressed before starting TRT, either by using alternatives like clomiphene or enclomiphene, or by adding HCG to maintain testicular function.

The cardiovascular discussion references the TRAVERSE trial, which Attia views as largely reassuring while acknowledging the signals around pulmonary embolism and atrial fibrillation. His overall take is that the cardiovascular risk of well-managed TRT in appropriate candidates is low and likely outweighed by the metabolic benefits of treating hypogonadism.

Acne, hair loss, and mood effects are covered as quality-of-life side effects that are real but manageable. Attia's clinical approach is to address these through protocol optimization first (dose adjustment, injection frequency) before reaching for additional medications.

Optimal Dosing: The Attia Protocol

Attia's dosing philosophy is conservative and individualized. He typically starts patients on testosterone cypionate at approximately 100mg per week, administered in divided doses (twice weekly at minimum, sometimes every other day). He uses both total and free testosterone as targets, generally aiming for free testosterone in the upper quartile of the reference range while keeping total testosterone within physiological limits.

He places significant emphasis on SHBG (sex hormone binding globulin) as a factor that determines how much of your total testosterone is biologically available. Men with high SHBG may have a total testosterone that looks adequate on paper while their free testosterone is actually low. Conversely, men with low SHBG may have free testosterone that is effectively higher than their total number suggests. Understanding your SHBG helps your provider determine the right dose and may influence the choice of delivery method.

The dosing schedule discussion is noteworthy. Attia is firmly in the camp of more frequent dosing, noting that the goal is to minimize the trough-to-peak ratio. He acknowledges that daily or every-other-day dosing can be impractical for some patients and works with each individual to find the highest frequency they will comply with consistently.

What Makes This Discussion Stand Out

The most valuable aspect of Attia's TRT discussions is the framework. He treats testosterone as a medical intervention with a clear risk-benefit profile rather than either a miracle cure or a dangerous drug. His insistence on thorough monitoring, conservative starting doses, and individualized optimization reflects best practices in the field and provides a model that patients can use to evaluate whether their own providers are meeting a high standard of care.

The longevity context also adds a dimension that most TRT content misses. Attia is more than asking whether TRT makes you feel better at 45. He is asking whether the metabolic, muscular, cognitive, and bone density benefits of TRT at 45 translate into better health at 65, 75, and beyond. This long-term perspective shifts the conversation from symptom management to health optimization in a way that is both more ambitious and more responsible.

Who Should Watch This

This video is particularly valuable for men who want a thorough, physician-level discussion of TRT without the hype. If you are weighing the decision of whether to start TRT, this is one of the most balanced presentations of the case for and against treatment that you will find. It is also useful for men who are already on TRT and want to evaluate whether their protocol meets the standard of care that Attia outlines. And it is an excellent video to share with a hesitant primary care physician who might benefit from hearing the perspective of a respected colleague in the field.

Applying This Framework to Your Own Situation

The value of Attia's approach lies more than in the specific recommendations but in the framework itself. He treats each patient as an individual case with unique physiology, health history, and goals. He uses data (bloodwork, body composition, symptom tracking) to drive decisions rather than applying a one-size-fits-all protocol. He starts conservative and adjusts iteratively. And he considers the long-term trajectory rather than optimizing only for how someone feels today.

You can apply this framework to your own TRT management regardless of who your provider is. Track your symptoms consistently. Get thorough bloodwork at regular intervals. Advocate for changes when your data suggests they are needed. Consider the long-term implications of your protocol, more than the short-term benefits. And find a provider who is willing to engage in this kind of collaborative, data-driven optimization rather than treating TRT as a set-and-forget prescription.

The fact that this video has over 700,000 views suggests a massive appetite for this kind of thoughtful, evidence-based TRT discussion. The men watching are not looking for hype. They are looking for clarity. And Attia delivers it in a way that respects both the science and the individual, which is exactly what the TRT conversation needs more of. Whether you are considering starting TRT, currently optimizing your protocol, or simply trying to understand the space, this video provides a foundation of knowledge that will serve you well.

If you leave this video with one takeaway, let it be this: TRT is a precision medical intervention, not a blunt instrument. The difference between a good outcome and a mediocre one often comes down to the details of dosing, monitoring, and management. Invest in getting those details right, and the return on that investment compounds over years and decades of better health.

The Evidence Base Continues to Grow

The scientific understanding of testosterone therapy is deepening every year. New studies are exploring the effects of TRT on Alzheimer's prevention, type 2 diabetes management, frailty in aging populations, and quality of life in cancer survivors. While many of these research areas are still in early stages, they point toward a future where TRT is viewed more than as a treatment for low libido and fatigue but as a potentially important intervention for age-related disease prevention.

Attia is well-positioned to interpret this emerging evidence because his practice sits at the intersection of hormonal health and longevity medicine. His willingness to evolve his approach as new data becomes available is one of the hallmarks of evidence-based practice, and it means that the recommendations in this video reflect the best current understanding rather than dogma from a previous era. Following practitioners like Attia who update their practice in real time with emerging evidence gives you access to the most current and effective approaches to testosterone management.

For viewers, the practical implication is that the TRT conversation is still evolving. What we know today is substantially more than what we knew five years ago, and what we will know five years from now will be more still. Staying engaged with the science, asking questions, and maintaining a relationship with a provider who keeps current gives you the best chance of benefiting from advances as they happen rather than being stuck with outdated protocols based on old information.